MLMaria Gabriela Gomes de Lima

Maria Gabriela Gomes de Lima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria Gabriela Gomes de Lima has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antagonistic potential of endophytic bacteria from tomato seedlings

    by Milena Campos de Oliveira Alencar Viana, Júlia Karoline Ferreira Moura, Maria Gabriela Gomes de Lima, Igor Daniel Alves Ribeiro, Luciane Maria Pereira Passaglia, Marcos Cabral de Vasconcellos Barreto, Pedro Roberto Almeida Viégas, Regina Helena Marino

    The objective of this work was to evaluate the antagonistic potential of endophytic bacteria isolated from 'Cereja Vermelho', 'Rasteiro Rio Grande', and 'Chapolin' tomato seedlings against the ALT23 Alternaria sp. fungus. Of the 23 endophytic isolates obtained, 12 were selected due to their greater effect on the mycelial growth of ALT23. Antagonism was tested in a completely randomized design, with 13 treatments (ALT23 and 12 isolates), with four replicates. The selected endophytic bacteria inhibited from 29.8 to 64.2% of the mycelial diameter and from 33.7 to 72.4% of the growth rate of ALT23.


  • Open Access

    Endophytic bacteria from lettuce seedlings antagonistic to the phytopathogenic fungus Alternaria sp.

    by Maria Gabriela Gomes de Lima, Milena Campos de Oliveira Alencar Viana, Júlia Karoline Ferreira Moura, Igor Daniel Alves Ribeiro, Luciane Maria Pereira Passaglia, Marcos Cabral de Vasconcellos Barretto, Francisco Sandro Rodrigues Holanda, Regina Helena Marino

    Endophytic microorganisms in lettuce plants have received little attention for their potential biological control of phytopathogens. This study aimed to isolate, identify, and select endophytic bacteria from lettuce seedlings cv. Brava and Creta, antagonistic to the phytopathogenic fungus Alternaria sp. (ALT23) in culture media through direct interaction. The experimental design was completely randomized in an 11 x 2 factorial scheme, with 11 treatments [Control - ALT23 and 10 previously selected bacterial isolates] and two evaluation periods (the 5th and 8th day after inoculation) with four replications each. The 16S rDNA gene sequences of the isolates revealed a high similarity with Bacillus tequilensis KCTC 13622, B. subtilis NCIB 3610, B. velezenzis CR-502, B. siamensis KCTC 13613, and Paenibacillus polymyxa ATCC 842. The selected bacterial isolates reduced ALT23 mycelial diameter (46.2-65.3%) and rate (51.8-91.6%). We conclude that endophytic bacterial isolates with antagonistic potential against phytopathogens must be selected after more than five days of cultivation in a culture medium, as longer cultivation times favor endophyte inhibitory activity.


  • Interleukin-2 and granulocyte–macrophage–colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer

    by Yee Chung Cheng, Gabriela Rondón, Leah F. Sanchez, John D. McMannis, Daniel R. Couriel, Marcos J. de Lima, Chitra Hosing, Issa F. Khouri, Sergio A. Giralt, Richard E. Champlin, et al.

    Immunomodulation with cytokines was used to improve the result of high-dose chemotherapy (HDC)/autologous hematopoietic stem cell transplantation (AHST). We examined the use of IL-2 and growth factors for mobilization, ex vivo activation of peripheral blood stem cell (PBSC) and maintenance therapy after HDC/AHST in metastatic breast cancer. Eligible patients with metastatic breast cancer for HDC/AHST were assigned to 1 of 3 protocols for PBSC mobilization: G-CSF (group 1); IL-2 + G-CSF (group 2); or IL-2 + G-CSF + GM–CSF (group 3). HDC with cyclophosphamide, carmustine and thiotepa was given from day −7 to −5. PBSCs were treated ex vivo with IL-2 for 24 h and reinfused on day 0. Maintenance therapy included low-dose IL-2, followed by 2 courses of intermediate-dose IL-2. GM–CSF was given from day 1 until neutrophil recovery. Thirty-four patients (10 in group 1, 14 in group 2, and 10 in group 3) were included. Comparable numbers of CD34+ cells were collected from all 3 groups; incremental increases of CD3+ cells were collected from groups 1 to 2 and to 3 (p = 0.03). Major adverse effects from IL-2 were fever, hypotension and fatigue; no treatment-related mortality was seen. At a median follow-up of 790.5 days (range 150–2,722 days), median progression-free survival was 434 days and median overall survival was 1,432 days. Estimated 3-year progression-free and overall survival rates were 31 and 57%. Our study suggested that the use of IL-2 and growth factors immunomodulation with HDC/AHST was feasible with comparable survival rates.


  • Open Access

    Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).

    by Uday Popat, Chitra Hosing, Michelle Fanale, L. Jeffrey Medeiros, Amin M. Alousi, Sergio A. Giralt, Marcos J. de Lima, Muzaffar H. Qazilbash, Partow Kebriaei, Anas Younes, et al.

    Abstract 2310 Poster Board II-287